Cetuximab

Red

Brand Name(s):Erbitux

Indication:Mutation-positive metastatic colorectal cancer in adults

Colorectal cancer (metastatic) only (First-line treatment

Rationale:1,2,3,8

Considered:Apr-09

Review Date:Jan-26

Comments:
NICE TA668 recommends encorafenib plus cetuximab, as an option for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment only if the company provides it according to the commercial arrangements.

MHRA Drug Safety Update
Importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer; http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON377644

February 2014